View Article

Abstract

An ulcer may result from excessive HCl production from the parietal cell due to hyperactivity of the H+/K+-ATPase enzyme, which damages the mucosal cell and causes bleeding.[1] The purpose of this study was to assess the preventable effects of a combination of omeprazole, zingiber, and aloe vera. Herbal ingredients have long been utilized as phytogenic agents to prevent and treat peptic ulcers.[2] Among herbal medications, alve vera and zingiber officinale have been widely utilized and their clinical effects have been recorded. This kind of combination medication lessens the negative effects of PPIs (Omeprazole).[1,2]When the H+/K+-ATPase enzyme is hyperactive, the parietal cell produces too much HCl, which destroys the mucosal cell and causes bleeding. This can lead to an ulcer.[4] This study aimed to evaluate the avoidable effects of a combination of aloe vera, zingiber, and omeprazole.[6] Peptic ulcers have long been prevented and treated with the use of herbal compounds as phytogenic agents. Herbal medicines such as alve vera and zingiber officinale have been used extensively and their therapeutic effects documented; this type of combination medication reduces the adverse effects of PPIs (omeprazole).[7] Ethnomedical methods also employ a variety of plant ulcers. This article looks at medicinal plants that have phytochemicals with gastroprotective and antiulcer qualities.[9]

Keywords

Peptic ulcer , Alove vera , Zingiber officinal , Omeprazole

Introduction

× Popup Image

The word "ulcer" first emerged in the Old French word ulcere, which is derived from the Latin word ulcus, which meaning "ulcer," before 1200 CE. The word also originated in French and crossed the English Channel.[11] The word "ulcer" means "painful area, Ulceration occurs when either increased aggressiveness or decreased mucosal resistance break the natural balance. Numerous factors are associated with the pathophysiology of stomach ulcers. The ideal objectives of treatment for peptic ulcer disease are pain reduction, ulcer healing, and ulcer recurrence prevention.[12, 13]

2 Peptic  Ulcer

 A hole in the stomach, duodenum, or esophagus's lining is known as a peptic ulcer. Gastric ulcers, duodenal ulcers, and esophageal ulcers are the terms used to describe peptic ulcers of the stomach, duodenum, and esophagus, respectively. The stomach's parietal cells secrete acidic digesting fluids that corrode the lining of these organs, causing an ulcer.

3 Types

  • Gastric peptic ulcer
  • Duodenal peptic ulcer

3.1 Gastric peptic ulcer –

A gastric ulcer is a rupture in the mucosa of the stomach lining that penetrates the muscularis mucosa and is larger than 5 mm in diameter. The gastric mucosa may alter as a result of modifications to the stomach's defense mechanisms, which may eventually cause erosion and ulceration.[19]

3.2 Duodenal peptic ulcer

Duodenal ulcers occur when the mucosa of the duodenum is damaged. Peptic ulcer disease, which encompasses these ulcers, affects the stomach and the first portion of the duodenum. This exercise reviews the evaluation and treatment of duodenal ulcers and explains the role of the interprofessional team in improving patient care.[20]

4. cause

There are major cause of peptic ulcer –

  • H pyloric bacteria
  • Non stroidal  Anti-iflammatory drug (NSAIDs)
  • Other factor
  • Smoking
  • Caffeine
  • Alcohal
  • Stress

4.1 H pyloric bacteria

H. pylori is now believed to be the cause of the majority of ulcers (Cover & Blaser, 1992). The H. pylori bacteria found in the stomach can damage the tissue of the stomach and duodenum, causing inflammation and ulcers, when paired with the creation of acid. The mucous membranes of the digestive tract are home to a bacterium known as Helicobacter pylori. Ninety-five percent of duodenal ulcers and seventy percent of stomach ulcers have been linked to H. pylori.[22]

4.2 Nonsteroidal anti-inflammatory drug (NSAIDs)

Aspirin, other NSAIDs, and corticosteroids are among the many drugs that might irritate the stomach lining and cause ulcers. Most people who take corticosteroids and NSAIDs do not suffer peptic ulcers.25. For people who are at a high risk of developing peptic ulcers, some doctors recommend coxibs (COX-2 inhibitors), which are less likely to irritate the stomach, instead of an older class of NSAIDs.[25]

 

 

 

 

Table 4.1 Peptic ulcer risk by specific NSAIDs

Lowest Risk

Midium Risk

Highest Risk

Nabumetone (Relafen)

Etodolac (Lodine)

Salsalate

Sulindac (Clinoril)

 

Aspirin. Even low-dose aspirin (81 mg) used to protect the heart may pose some risk (although lower than standard doses).

Ibuprofen (Motrin, Advil, Nuprin, Rufen)

Naproxen (Aleve, Naprosyn, Naprelan, Anaprox)

Diclofenac (Voltaren)

Tolmetin (Tolectin)

Flurbiprofen (Ansaid)

Piroxicam (Feldene)

Fenoprofen

Indomethacin (Indocin)

Meclofenamate (Meclomen)

Ketoprofen (Action, Orudis KT)

 

 

4.3 Other factor

may also make a person more susceptible to ulcers, for instance. Smokers have a higher risk of both developing an ulcer and dying from an ulcer's complications.[27]
Gastric mucus, the stomach's surface cells, bicarbonate ions (which neutralize acid), and compounds known as prostaglandins protect the stomach from ulcers. In addition, ischemia, decreased mucosal blood flow, acid, free radicals, prostaglandin, hyperglycemia, angiotensin II, nicotine, thyrotropin-releasing hormone (TRH), and bile salts can all lead to stress ulcers. [28]In addition to these, there are a few other factors, such as:

Smoking: Research has shown that smoking cigarettes increases the risk of ulcers. Furthermore, smoking prevents pre-existing ulcers from healing and encourages ulcer recurrence.[28]

Caffeine: Caffeine-containing foods and beverages might increase the stomach's production of acid. This may exacerbate an ulcer that already exists, but caffeine alone is not responsible for the production of stomach acid.[28]

Stress: People who experience emotional stress often report that their pre-existing ulcers pain worse, even though it is no longer thought that emotional stress causes ulcers. Physical stress, however, is different. It might increase the risk of ulcers, especially in the stomach. Physical factors that might cause ulcers include people with injuries such as serious burns and those having major surgery.[28]As shown below, ulcerogens have mostly targeted acid secretion and disruption of mucosal defense (Figure 1.4 & 1.5). Understanding the physiological control in stomach cells becomes evident prior to comprehending their targeted involvement during ulcerogenesis. Since H+, K+-ATPase, and mucosal defense have been essential for,regulating.[28]

5. Diagnosis of Ulcer

A physical examination and many diagnoses can be used to make a diagnosis.[30]Physical examination: The most common finding in patients with duodenal or stomach ulcers is epigastric pain. Finding signs of ulcer complications requires a physical examination. Orthostasis and tachycardia point to dehydration brought on either vomiting or active gastrointestinal blood loss. A perforation is suggested by an extremely sensitive, board-like abdomen.[29]

The most precise and targeted technique for evaluating the upper gastrointestinal system is endoscopy (Figure 1.10). In addition to providing direct view of the mucosa, endoscopy enables tissue collection and photographic documentation of a mucosal abnormality.[29]rule out cancer or H. pylori. Endoscopic examination is particularly useful for assessing uncommon radiographic anomalies, identifying lesions too small to be noticed by radiographic examination, or confirming whether an ulcer is the origin of blood loss.[29] The diagnostic procedure for H. pylori includes a urease test in the biopsy samples, which has a sensitivity and specificity of >90 to 95%. In an attempt to diagnose H. pylori without the need for endoscopy, a number of noninvasive methods have been developed.[29]

6. Effects of different PPIs on the parietal cell

The first PPI to be used in therapeutic settings was omeprazole, a derivative of benzimidazole. Later benzimidazole PPIs included lansoprazole, pantoprazole, and rabeprazole. Each of these compounds consists of a pyridine and a benzimidazole moiety, two heterocyclic components joined by a methyl sulfinyl,group.[1]
Omeprazole transforms into a sulfenamide analogue when acid is present, and this analogue inhibits the ATPase irreversibly by creating a covalent disulfide link with an essential sulfhydryl group in the active site. The enantiomerically pure S-isomer, esomeprazole, is marketed commercially as Nexium.[1]

Mode Of Action

 

 

 

 

7.  Plant Profile

  • Aleo vera 

Family name:              Liliaceae

Common name:          Aloe vera

Origin:                        It is perennial plant native to mediterranean and

african countries. it is cultivated in cyprus, india, malta

and sicily

Parts used:                  Leaf

Active constituent:       Saponin, barbaloin, isobarbaloin

Traditional uses:         Its gel is used in preparation of

beverages, lotions and cosmetics such as shampoos, razors,

moisturizers, soaps, sunscreens and makeup

Roles in human body: Detoxification, laxative, wound

healing, skin burns care, antiulcer, cytoprotective, anti-

fungal, hepatoprotective, immunostimulator, mucus

secreting and anti-diabetic.[30]

  • Zingiber officinale

Common name:          Ginger

 Family name:             Zingiberaceae  (Ginger family)

Parts used:                 Rhizome

Active constituents: Gingerols (especially 6-gingerol), Shogaols, Zingerone

Traditional use:  Relief of nausea and vomiting (motion sickness, pregnancy-related nausea),Treatment of colds and cough, Digestive aid (indigestion, bloating, flatulence), Anti-inflammatory remedy for joint pain.

Roles in the human body:     Stimulates digestive enzymes and improves gut motility,

Acts as an anti-inflammatory by inhibiting prostaglandins and leukotrienes,      Antioxidant activity (reduces oxidative stress).[30]

8. MATERIALS AND METHODS

FORMULATION DEVELOPMENT OF OMEPRAZOLE SODDELAYED RELEASE TABLETS

Formula for preparation of Omeprazole Sodium core tablets

 

S.NO

Ingredient (mg)

Formulation code

 

F1

F2

F3

F4

F5

1

Omeprazole

20

20

20

20

20

2

Mannitol

96.5

76.5

78.5

60.5

43.5

3

Heavy magnesium oxide

10

30

30

50

50

4

Hydroxy propyl cellulose

5

5

3

1

1

5

L-HPC-LH-21

15

15

15

15

30

6

Crospovidone

q.s

q.s

q.s

q.s

q.s

7

Isopropyl alcohol

q.s

q.s

q.s

q.s

q.s

8

Aloe vera

q.s

q.s

q.s

q.s

q.q

9

Zingiber officinale

q.s

q.s

q.s

q.s

q.s

 

9. PREPARATION OF TABLETS

Step 1: Weighing & Sifting

  • Accurately weigh all ingredients.
  • Pass Omeprazole, Mannitol, L-HPC, Crospovidone through. 
  • Pass HPC separately through.

 Step 2: Dry Mixing

  • Transfer Omeprazole + Mannitol into a mortar or blender.
  • Mix for 10–15 minutes to ensure uniform distribution.
  • Add L-HPC and Crospovidone, mix again for 5–10 minutes.

Step 3: Preparation of Binder Solution

  • Dissolve Hydroxypropyl Cellulose (HPC) in Isopropyl Alcohol.
  • Stir until a clear binder solution is formed.

Step 4: Wet Granulation

  • Slowly add binder solution to the powder blend.
  • Mix until a cohesive wet mass is obtained.
  • Avoid overwetting (important for omeprazole stability).

Step 5: Granule Formation

  • Pass wet mass through #16 or #20 sieve to form granules.

Step 6: Drying

  • Dry granules at 40°C–45°C (tray dryer or air dry).
  • Avoid high temperature (Omeprazole is heat sensitive).
  • Dry until moisture content < 2%.

Step 7: Sizing

  • Pass dried granules through #20 sieve for uniform size.

Step 8: Lubrication (Optional if needed)

  • If required, add a small amount of lubricant (e.g., magnesium stearate ~1–2%) and mix gently.

tep 9: Compression

  • Compress granules using a tablet punching machine.

10. EVALUATION STUDIES OF OMEPRAZOLE DELAYED RELEASE TABLETS

a)Dissolution

the drug is released over time in different pH environments (simulating stomach → intestine).

TABLE NO-10.1

EVALUATION PARAMETER

FORMULATION (min.)

F1

F2

F3

F4

F5

DISSOLUTION TEST

62

54

52

48

65

 

 

 

Fig No.- 10.1

b) Hardness:

To endure the mechanical shocks of handling during production, packaging, and transportation, tablets need to have a specific level of strength, or hardness and resistance to friability. The force needed to break a tablet during a diametric compression test is known as tablet hardness. A hardness tester was used to measure hardness.

TABLE NO.5.2

EVALUTION PARAMETRE

FORFULATION

F1

F2

F3

F4

F5

HARDNESS TEST

6

4.50

3.50

5

4

 

 

Fig No.- 10.2

c) Weight variation test:

In order to guarantee that a tablet has the right amount of medication, the weight of the tablet was regularly measured. Tablets are made to include a specified amount of medication in a specific amount of tablet formula.
Twenty pills were chosen at random, their individual weights were recorded, and the average weight of the tablets was calculated. The average weight was not exceeded by more than two of the individual weights.

(Weight of tablet (mg) - Average weight of tablet (mg))

 Percentage deviation =---------------------------------------------------------×100

TABLE NO.-10.3

EVALUTION PARAMETER

FORMULATION (mg)

F1

F2

F3

F4

F4

Weight Variation

0.52

0.30

0.41

0.49

0.53

 

 

Fig No.-10.3

d) Friability:

The weight loss of the tablet in the container as a result of the small particles being removed from its surface is known as friability. Roche Friabilator was used to assess the tablet's friability. The percentage (%) was used to express it. Twenty pills were put into the friabilator after being first weighed. For four minutes, the Friabilator was run at 25 rpm. The final weight of the tablets was measured once more. The following formula was then used to determine the percentage of friability.

Friability = Initial wt – Final wt / Initial

 wt X 100 Limit: Friability should be less than 1%.

TABLE NO.-10.4

EVALUATION TEST

FORMU;ATION

F1

F2

F3

F4

F5

FRIABILITY TEST

2%

0.47%

0.34%

0.60%

0.20%

 

 

Fig No.-10.4

e) Disintegration time:

Using a disintegration test instrument, the tablet's disintegration time was monitored.

TABLE NO.-10.5

EVALUATION TEST

FORMULATION TEST

F1

F2

F3

F4

F5

DISINTEGRATION TEST

9

17

11

14

15

 

 

Fig NO. 10.5

CONCLUSION

Omeprazole delayed-release tablets are successfully formulated utilizing the wet granulation method, which guarantees the stability of the acid-labile medication and enables targeted drug release in the digestive region through enteric coating. Good flow characteristics, compressibility, and efficient tablet core disintegration are all facilitated by the use of appropriate excipients like mannitol, hydroxypropyl cellulose, L-HPC, and crospovidone.

Additional therapeutic benefits, such as gastroprotective, anti-inflammatory, and antioxidant properties, can be obtained by using herbal agents such as Aloe barbadensis Miller and Zingiber officinale. These herbal remedies could improve the formulation's overall safety profile and lessen stomach discomfort.All things considered, combining pharmaceutical formulation with herbal supplementation is a potential way to enhance omeprazole therapy's effectiveness, stability, and patient compliance. To verify the improved safety and therapeutic efficacy of this combination system, more research is advised, including in-vitro and in-vivo assessments.

RESULT

The formulated Omeprazole delayed-release tablets prepared by the wet granulation method showed satisfactory physicochemical properties.

 

 

Sr. No.

Parameter

Method/Instrument

Acceptance Criteria

1

Appearance

Visual inspection

Uniform color, no cracks/defects

2

Size & Shape

Visual / Vernier caliper

Consistent and uniform

3

Thickness

Vernier caliper / Screw gauge

±5% variation allowed

4

Diameter

Vernier caliper

Uniform for all tablets

5

Weight Variation

Digital balance (20 tablets)

Within pharmacopeial limits (±5–10%)

6

Hardness

Monsanto/Pfizer tester

4–8 kg/cm² (typical)

7

Friability

Roche friabilator

≤ 1% weight loss

 

REFERENCES

  1. Agrawal, A. K.; Rao, C. V.; Sairman, K.; Joshi, V. K. and Goel, R. K.(2000):

Effect of Piper longum linn, Zingiber officianails linn and Ferula species on gastric ulceration and secretion in rats. J. of Exp. Biol., 38 (10): 994-99

  1. Ahmad, A.; Husain, A.; Mujeeb, M.; Khan, S. A.; Najmi, A. K. and Siddique, N. A. (2013): A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pac J Trop Biomed; 3(5): 337-52.
  2. Akhtar, A. H. and Ahmed, K. U. (1995): Anti- ulcerogenic evaluation of the methanolic extracts of some indigenous medicinal plants in Pakistan on aspirin-ulcerated rats. J. Ethnopharmacol.; 46(1): 1-6.
  3. Al Batran, R.; Al-Bayaty, F.; Jamil Al-Obaidi, M. M.; Abdualkader, A. M.; Hadi, H. A. and Ali, H. M. (2013): In vivo antioxidant and antiulcer activity of Parkia speciosa ethanolic leaf extract against ethanol-induced gastric ulcer in rats. PLoS One; 8(5): e64751.
  4. Bardocz, S.; Grant, G.; Ewen, S. W. D.; Dunguid, T. J.; Brown, D. S.; Englyst, K. and Pusztai, A. (1995): Reversible effect of phytohaemaglutinins on the growth and metabolism of rat gastrointestinal tract. Gut.; 37: 353–360
  5. Bashinskaya, B.; Nahed, B. V.; Redjal, N.; Kahle, K. T. and Walcott, B. P. (2011): Trends in peptic ulcer disease and the identification of helicobacter pylori as a causative organism: population-based estimates from the US nationwide inpatient sample, J. Glob. Infect. Dis.; 3 (4): 366-370.
  6. Borra, S. K.; Lagisetty, R. K. and Mallela, G. R. (2011): Anti-ulcer effect of Aloe vera in non-steroidal anti-inflammatory drug induced peptic ulcers in rats. African Journal of Pharmacy and Pharmacology Vol.; 5(16), pp. 1867-1871. DOI: 10.5897/AJPP11.306.
  7. El-Abhar, H.; Abdallah, D. and Saleh, S. (2002): Gastroprotective, activity of Nigella sativa oil and its constituent, thymoquinone, against gastric mucosal injury induced by ischemia/reperfusion in rats. J. Ethnopharmacol.; 84: 251- 258
  8. Fallahi, M.; Soroush, A.; Sadeghi, N.; Mansouri, F.; Mobaderi, T. and Mahdavikian, S. (2022): Comparative Evaluation of the Effect of Aloe Vera Gel, Olive Oil, and Compound Aloe Vera Gel-Olive Oil on Prevention of Pressure Ulcer: A Randomized Controlled Trial. Adv Biomed Res.; 31; 11:6. Doi: 10.4103/abr.abr_121_21

 

  1. Weberg, R.; Berstad, K. and Berstad, A. (1990):Acute effects of antacids on gastric juice components in duodenal ulcer patients. Eur J Clin Invest.; 20:511-515.
  2. Teradaira, R.; Shinzato, M.; Bepp, U. H. and Fujita, K. (1993): Antigastric ulcer effects in rats of Aloe arborescens Miller var. natalensis Berger extract. Phytother Res.; 7: 34-36.
  3. University of Michigan Health System. Peptic ulcer disease. Accessed May 4, 2007, at: http://www.cme.med.umich.edu/pdf/guideline/PUD05.pdf
  4. Sonnenberg A, Everhart JE. The prevalence of self-reported peptic ulcer in the United States. Am J Public Health 1996;86:200-5.
  5. Kang JY, Tinto A, Higham J, Majeed A. Peptic ulceration in general practice in England and Wales 1994-98: period prevalence and drug management. Aliment Pharmacol Ther 2002;16:1067-74
  6. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997;24:2-17
  7. Ziegler AB. The role of proton pump inhibitors in acute stress ulcer prophylaxis in mechanically ventilated patients. Dimens Crit Care Nurs 2005;24:109-14.
  8. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994;272:65-9.
  9. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997;112:683-9.
  10. Hilton D, Iman N, Burke GJ, Moore A, O’Mara G, Signorini D, et al. Absence of abdominal pain in older persons with endoscopic ulcers: a prospective study. Am J Gastroenterol 2001;96:380-4.
  11. Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756-80
  12. Treiber G, Wittig J, Ammon S, Walker S, van Doorn L, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002;162:153-60.
  13. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995;7:661-5.
  14. Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003;18:559-68.
  15. Behrman SW. Management of complicated peptic ulcer disease. Arch Surg 2005;140:201-8
  16. Lanas AI, Remacha B, Esteva F, Sainz R. Risk factors associated with refractory peptic ulcers. Gastroenterology 1995;109:1124-33.
  17. eura DA. Prevention of non-steroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med 2004;177 (suppl 5A):63S-71S.
  18. Palanivelu C, Jani K, Rajan PS, Kumar KS, Madhankumar MV, Kadalakat A. Laparoscopic management of acid peptic disease. Surg Laparosc Endosc Percutan Tech 2006;16:312-6.
  19. Hernandez-Diaz S, Rodriguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 2002;55:157-63.
  20. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;38:316-21.
  21. Leontiadis GI, Sharma VK, Howden CW. Systematic review and metaanalysis: proton-pump inhibitor treatment for ulcer bleeding reduces transfusion requirements and hospital stay—results from the Cochrane Collaboration. Aliment Pharmacol Ther 2005;22:169-74
  22. Eisen GM, Dominitz JA, Faigel DO, Goldstein JL, Kalloo AN, Petersen BT, et al., for the American Society for Gastrointestinal Endoscopy. Standards of Practice Committee. An annotated algorithmic approach to upper gastrointestinal bleeding. Gastrointest Endosc 2001;53:853-8.
  23. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz E. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004;19:617-29.
  24. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9
  25. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;(4):CD002296
  26. Shone DN, Nikoomanesh P, Smith-Meek MM, Bender JS. Malignancy is the most common cause of gastric outlet obstruction in the era of H2 blockers. Am J Gastroenterol 1995;90:1769-70.

Reference

  1. Agrawal, A. K.; Rao, C. V.; Sairman, K.; Joshi, V. K. and Goel, R. K.(2000):

Effect of Piper longum linn, Zingiber officianails linn and Ferula species on gastric ulceration and secretion in rats. J. of Exp. Biol., 38 (10): 994-99

  1. Ahmad, A.; Husain, A.; Mujeeb, M.; Khan, S. A.; Najmi, A. K. and Siddique, N. A. (2013): A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pac J Trop Biomed; 3(5): 337-52.
  2. Akhtar, A. H. and Ahmed, K. U. (1995): Anti- ulcerogenic evaluation of the methanolic extracts of some indigenous medicinal plants in Pakistan on aspirin-ulcerated rats. J. Ethnopharmacol.; 46(1): 1-6.
  3. Al Batran, R.; Al-Bayaty, F.; Jamil Al-Obaidi, M. M.; Abdualkader, A. M.; Hadi, H. A. and Ali, H. M. (2013): In vivo antioxidant and antiulcer activity of Parkia speciosa ethanolic leaf extract against ethanol-induced gastric ulcer in rats. PLoS One; 8(5): e64751.
  4. Bardocz, S.; Grant, G.; Ewen, S. W. D.; Dunguid, T. J.; Brown, D. S.; Englyst, K. and Pusztai, A. (1995): Reversible effect of phytohaemaglutinins on the growth and metabolism of rat gastrointestinal tract. Gut.; 37: 353–360
  5. Bashinskaya, B.; Nahed, B. V.; Redjal, N.; Kahle, K. T. and Walcott, B. P. (2011): Trends in peptic ulcer disease and the identification of helicobacter pylori as a causative organism: population-based estimates from the US nationwide inpatient sample, J. Glob. Infect. Dis.; 3 (4): 366-370.
  6. Borra, S. K.; Lagisetty, R. K. and Mallela, G. R. (2011): Anti-ulcer effect of Aloe vera in non-steroidal anti-inflammatory drug induced peptic ulcers in rats. African Journal of Pharmacy and Pharmacology Vol.; 5(16), pp. 1867-1871. DOI: 10.5897/AJPP11.306.
  7. El-Abhar, H.; Abdallah, D. and Saleh, S. (2002): Gastroprotective, activity of Nigella sativa oil and its constituent, thymoquinone, against gastric mucosal injury induced by ischemia/reperfusion in rats. J. Ethnopharmacol.; 84: 251- 258
  8. Fallahi, M.; Soroush, A.; Sadeghi, N.; Mansouri, F.; Mobaderi, T. and Mahdavikian, S. (2022): Comparative Evaluation of the Effect of Aloe Vera Gel, Olive Oil, and Compound Aloe Vera Gel-Olive Oil on Prevention of Pressure Ulcer: A Randomized Controlled Trial. Adv Biomed Res.; 31; 11:6. Doi: 10.4103/abr.abr_121_21

 

  1. Weberg, R.; Berstad, K. and Berstad, A. (1990):Acute effects of antacids on gastric juice components in duodenal ulcer patients. Eur J Clin Invest.; 20:511-515.
  2. Teradaira, R.; Shinzato, M.; Bepp, U. H. and Fujita, K. (1993): Antigastric ulcer effects in rats of Aloe arborescens Miller var. natalensis Berger extract. Phytother Res.; 7: 34-36.
  3. University of Michigan Health System. Peptic ulcer disease. Accessed May 4, 2007, at: http://www.cme.med.umich.edu/pdf/guideline/PUD05.pdf
  4. Sonnenberg A, Everhart JE. The prevalence of self-reported peptic ulcer in the United States. Am J Public Health 1996;86:200-5.
  5. Kang JY, Tinto A, Higham J, Majeed A. Peptic ulceration in general practice in England and Wales 1994-98: period prevalence and drug management. Aliment Pharmacol Ther 2002;16:1067-74
  6. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997;24:2-17
  7. Ziegler AB. The role of proton pump inhibitors in acute stress ulcer prophylaxis in mechanically ventilated patients. Dimens Crit Care Nurs 2005;24:109-14.
  8. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994;272:65-9.
  9. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997;112:683-9.
  10. Hilton D, Iman N, Burke GJ, Moore A, O’Mara G, Signorini D, et al. Absence of abdominal pain in older persons with endoscopic ulcers: a prospective study. Am J Gastroenterol 2001;96:380-4.
  11. Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756-80
  12. Treiber G, Wittig J, Ammon S, Walker S, van Doorn L, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002;162:153-60.
  13. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995;7:661-5.
  14. Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003;18:559-68.
  15. Behrman SW. Management of complicated peptic ulcer disease. Arch Surg 2005;140:201-8
  16. Lanas AI, Remacha B, Esteva F, Sainz R. Risk factors associated with refractory peptic ulcers. Gastroenterology 1995;109:1124-33.
  17. eura DA. Prevention of non-steroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med 2004;177 (suppl 5A):63S-71S.
  18. Palanivelu C, Jani K, Rajan PS, Kumar KS, Madhankumar MV, Kadalakat A. Laparoscopic management of acid peptic disease. Surg Laparosc Endosc Percutan Tech 2006;16:312-6.
  19. Hernandez-Diaz S, Rodriguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 2002;55:157-63.
  20. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;38:316-21.
  21. Leontiadis GI, Sharma VK, Howden CW. Systematic review and metaanalysis: proton-pump inhibitor treatment for ulcer bleeding reduces transfusion requirements and hospital stay—results from the Cochrane Collaboration. Aliment Pharmacol Ther 2005;22:169-74
  22. Eisen GM, Dominitz JA, Faigel DO, Goldstein JL, Kalloo AN, Petersen BT, et al., for the American Society for Gastrointestinal Endoscopy. Standards of Practice Committee. An annotated algorithmic approach to upper gastrointestinal bleeding. Gastrointest Endosc 2001;53:853-8.
  23. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz E. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004;19:617-29.
  24. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9
  25. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;(4):CD002296
  26. Shone DN, Nikoomanesh P, Smith-Meek MM, Bender JS. Malignancy is the most common cause of gastric outlet obstruction in the era of H2 blockers. Am J Gastroenterol 1995;90:1769-70.

Photo
Shweta Ram
Corresponding author

Rungta Institute of Pharmaceutical Sciences, Bhilai

Photo
Dharmesh Koushal
Co-author

Rungta Institute of Pharmaceutical Sciences, Bhilai

Photo
Sushmita Pradhan
Co-author

Rungta Institute of Pharmaceutical Sciences, Bhilai

Photo
Vimla
Co-author

Rungta Institute of Pharmaceutical Sciences, Bhilai

Photo
Suchita Wamankar
Co-author

Rungta Institute of Pharmaceutical Sciences, Bhilai

Photo
Dr. Gyanesh Sahu
Co-author

Rungta Institute of Pharmaceutical Sciences, Bhilai

Photo
Dr. Chanchal Deep Kaur
Co-author

Rungta Institute of Pharmaceutical Sciences, Bhilai

Dharmesh Koushal, Sushmita Pradhan, Vimla, Shweta Ram, Suchita Wamankar Dr. Gyanesh Sahu, Dr. Chanchal Deep Kaur, Formulation and Evaluation of Herbal-Integrated Omeprazole Delayed Release Tablets for Enhanced Gastroprotective Safety, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 4, 2219-2229, https://doi.org/10.5281/zenodo.19588685

More related articles
Phytochemical-Guided Formulation and Pharmacologic...
Komal Gutte, Akash Jadhav, Apeskha Jaybhaye, Dipti Kanke, Gayatri...
A Review on Nanoparticles: Synthesis, Characterisa...
Daiwashala Pawar, Ruchira Medankar, Sneha Wadu, Amol Ratke...
A Comprehensive Review on Stability-Indicating RP-...
Komal Humbe, Dr. H. Kamble, Sugriv Ghodke, Sonawane A...
Related Articles
Vonoprazan: A Novel Acid Suppressant in Clinical Practice ...
Tejaswini Kulkarni, K. Pansare, C. Patil, Komal Gangurde...
Formulation And Evaluation of Herbal Gel for Management of Mouth Ulcer ...
Kavita Sharma, Rushikesh Narode, Abhijeet Rekhate...
Phytochemical-Guided Formulation and Pharmacological Evaluation of Plumeria Alba...
Komal Gutte, Akash Jadhav, Apeskha Jaybhaye, Dipti Kanke, Gayatri Kale, Sameena Shaikh...
More related articles
Phytochemical-Guided Formulation and Pharmacological Evaluation of Plumeria Alba...
Komal Gutte, Akash Jadhav, Apeskha Jaybhaye, Dipti Kanke, Gayatri Kale, Sameena Shaikh...
A Review on Nanoparticles: Synthesis, Characterisation, and Applications in Phar...
Daiwashala Pawar, Ruchira Medankar, Sneha Wadu, Amol Ratke...
A Comprehensive Review on Stability-Indicating RP-HPLC Methods for the Estimatio...
Komal Humbe, Dr. H. Kamble, Sugriv Ghodke, Sonawane A...
Phytochemical-Guided Formulation and Pharmacological Evaluation of Plumeria Alba...
Komal Gutte, Akash Jadhav, Apeskha Jaybhaye, Dipti Kanke, Gayatri Kale, Sameena Shaikh...
A Review on Nanoparticles: Synthesis, Characterisation, and Applications in Phar...
Daiwashala Pawar, Ruchira Medankar, Sneha Wadu, Amol Ratke...
A Comprehensive Review on Stability-Indicating RP-HPLC Methods for the Estimatio...
Komal Humbe, Dr. H. Kamble, Sugriv Ghodke, Sonawane A...